Cheryl Gault
Vermogen: 6 M $ op 31-05-2026
Vermogen: 6 M $ op 31-05-2026
Cheryl Gault is currently Chief Operating Officer at Rapport Therapeutics, Inc. since 2023.
Formerly, Ms. Gault was Chief Operating Officer at Cyclerion Therapeutics, Inc. from 2021 to 2023, VP-Commercial Strategy & New Product Planning at Ironwood Pharmaceuticals, Inc. from 2017 to 2019, and held the position Head-Sales & Marketing at Genzyme Corp.
Education includes undergraduate studies at Boston College.
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
| 30-03-2026 | 159.914 ( 0,33% ) | 6 M $ | 31-05-2026 |
| Bedrijven | Functie | Begin |
|---|---|---|
| RAPPORT THERAPEUTICS, INC. | Operationeel Directeur | 07-09-2023 |
| Bedrijven | Functie | Einde |
|---|---|---|
| CYCLERION THERAPEUTICS, INC. | Operationeel Directeur | 28-07-2023 |
| IRONWOOD PHARMACEUTICALS, INC. | Corporate Officer/Principal | 01-04-2019 |
Genzyme Corp.
Genzyme Corp. Pharmaceuticals: MajorHealth Technology Develops and manufactures therapies for rare diseases, multiple sclerosis, immunology & oncology | Verkoop & Marketing | - |
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
| Bedrijven in privébezit | 5 |
|---|---|
Genzyme Corp.
Genzyme Corp. Pharmaceuticals: MajorHealth Technology Develops and manufactures therapies for rare diseases, multiple sclerosis, immunology & oncology | Health Technology |
Ironwood Pharmaceuticals, Inc.
Ironwood Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops, manufactures and markets gastrointestinal products | Health Technology |
Boston College
Boston College Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Cyclerion Therapeutics, Inc.
Cyclerion Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops and distributes pharmaceutical products for serious and orphan diseases | Health Technology |
Rapport Therapeutics, Inc.
Rapport Therapeutics, Inc. BiotechnologyHealth Technology Operates as an clinical-stage biotechnology company that engages in discovery and development of medicines for neurological disorder | Health Technology |
Kies jouw editie
Alle financiële informatie op nationaal niveau